Presentations by Rutgers Cancer Institute of New Jersey Faculty Members at the Virtual 2020 American Society of Clinical Oncology Annual Meeting

Talks and posters are being offered on-demand starting at 8 a.m., Friday, May 29 and will be available online through the end of August. Click [here](#) for additional information.

**Clinical Science Symposium**

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. [Abstract #6010](#)
Author: Eugenia Girda, MD, FACOG

**Oral Presentations**

“Novel Targeted Therapy Approaches”
Session Type: Melanoma/Skin Cancers
Discussant: Janice M. Mehnert, MD

“Melanoma Highlights”
Session Type: Highlights of the Day
Discussant: Janice M. Mehnert, MD

Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.
Session Type: Genitourinary Cancer
Author: Eric A. Singer, MD, MA, FACS

**Poster Sessions**

Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. [Abstract #8013](#)
Lead Author: Peter Cole, MD

LAG-3 overexpression in pediatric Hodgkin lymphoma. [Abstract #10531](#)
Lead Author: Scott Moerdler, MD
Senior Author: Peter Cole, MD

Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi). [Abstract #10029](#)
Senior Author: Janice Mehnert, MD
Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320. Abstract #10039
Author: Janice Mehnert, MD

Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study. Abstract #7540
Author: Andrew M. Evens, DO

Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites. Abstract #8043
Senior Author: Andrew M. Evens, DO

Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC). Abstract #12068
Senior Author: Andrew M. Evens, DO

Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. Abstract #9008
Lead Author: Salma K. Jabbour, MD

Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial. Abstract #9010
Author: Salma K. Jabbour, MD

The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC. Abstract #9032
Author: Salma K. Jabbour, MD

NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer. Abstract #TPS9082
Author: Salma K. Jabbour, MD

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. Abstract #4020
Author: Kristen Spencer, DO, MPH,

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174). Abstract #TPS4651
Author: Kristen Spencer, DO, MPH

Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057. Abstract #5041
Author: Eric A. Singer, MD, MA, FACS
Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC). Abstract #4062
Lead Author: Patrick M. Boland, MD

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). Abstract #TPS4121
Author: Patrick M. Boland, MD

Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study. Abstract #4032
Author: Patrick M. Boland, MD

Publication Only

Open label phase I trial using SPL-108 in combination with weekly paclitaxel final report with molecular correlates. Abstract #e18040
Lead Author: Eugenia Girda, MD
Authors: Alexandre Buckley de Meritens, MD, Ruth D. Stephenson, DO, FACOG, Aliza L. Leiser, MD, Mihae Song, MD

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. Abstract #6010
Author: Eugenia Girda, MD

Cyclooxygenase inhibitor use during checkpoint immunotherapy and effect on time to progression and overall survival for metastatic melanoma and non-small cell lung cancer patients. Abstract #e22034
Senior Author: Salma K. Jabbour, MD
Authors: Shang-Jui Wang, Karishma Khullar, Sinae Kim, PhD, Roman Groisberg, MD, Jyoti Malhotra, MD, Janice M. Mehnert, MD

Breast cancer receptor subtypes in East Africa: A systematic review and meta-analysis. Abstract #e19074
Authors: Coral Omene, MD, Shridar Ganesan, MD, PhD

Author: Eric A. Singer, MD, MA, FACS

Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Abstract #e17058
Senior Author: Thomas L. Jang, MD, MPH, FACS
Authors: Sinae Kim, PhD, Isaac Kim, MD, PhD, Eric A. Singer, MD, MA, FACS